');
document.write('
Boning up on the link between Fosamax and atypical fractures 93/18/10, BMJ Group) http://bit.ly/du2Dah');
document.write('');
document.write('
RT @swoodruff: 13 Observations From South by Southwest (SXSW) | Great summary by @jaybaer. Saved me the expense of going! http://ow.ly/1ntYK');
document.write(' RT @swoodruff: 13 Observations From South by Southwest (SXSW) | Great summary by @jaybaer. Saved me the expense of going! http://ow.ly/1ntYK');
document.write(' FDA And Novartis Announce A Label Change For Iron Chelating Drug Exjade In Mid-February 2010 http://bit.ly/cFEbAM');
document.write('
FDA And Novartis Announce A Label Change For Iron Chelating Drug Exjade In Mid-February 2010 - Drug Injury Watch');
document.write('');
document.write('');
document.write('
Boning up on the link between Fosamax and atypical fractures 93/18/10, BMJ Group) http://bit.ly/du2Dahfrom Twitter
RT @swoodruff: 13 Observations From South by Southwest (SXSW) | Great summary by @jaybaer. Saved me the expense of going! http://ow.ly/1ntYKfrom Facebook
RT @swoodruff: 13 Observations From South by Southwest (SXSW) | Great summary by @jaybaer. Saved me the expense of going! http://ow.ly/1ntYKfrom Twitter
FDA And Novartis Announce A Label Change For Iron Chelating Drug Exjade In Mid-February 2010 http://bit.ly/cFEbAMfrom Twitter
FDA And Novartis Announce A Label Change For Iron Chelating Drug Exjade In Mid-February 2010 - Drug Injury Watchfrom del.icio.us